

18 August 2025

Atopic Dermatitis

The service only has access to the following information below:

1. How many patients were treated in the last 4 months (April to July 2025) by the dermatology department with each of the following products:

- **Abrocitinib:** 9
- **Acitretin:** Not available
- **Alitretinoin:** Not available
- **Azathioprine:** Not available
- **Baricitinib:** <5
- **Ciclosporin:** Not available
- **Dupilumab:** 238
- **Lebrikizumab:** 7
- **Methotrexate:** Not available
- **Mycophenolate mofetil:** Not available
- **Pimecrolimus:** Not available
- **Phototherapy (UVB or PUVA) - for Atopic Dermatitis only:** Not available
- **Tacrolimus ointment:** Not available
- **Tralokinumab:** <5
- **Upadacitinib:** 36
- **Nemolizumab:** <5

2. In the last 4 months, how many new patients have been initiated* on the following treatments by the dermatology department

- **Abrocitinib:** <5
- **Baricitinib:** <5
- **Dupilumab:** 29
- **Lebrikizumab:** <5
- **Tralokinumab:** <5
- **Upadacitinib:** 6
- **Nemolizumab:** <5

*Patients are considered initiated on a treatment if they have not been treated with the named treatment in the previous 8 months.

18 August 2025

3. Of the patients treated in the last 4 months with any of the products listed in question 1, please provide the number of patients by the following age group:

- **6 months to 5:** <5
- **Age 6-11:** 15
- **Age 12-17:** 30
- **Age 18 and above:** 245

N.B. Use of less than five (<5) - We are not able to provide the information requested. The low numbers involved would reduce numbers to discoverable limits and, as a result, we consider that individuals could be identified and disclosure of this information would breach the first data protection principle, which relates to the fair and lawful processing of personal data. Therefore, we have concluded that this information is exempt from disclosure under Section 40(2) of the Freedom of Information Act - Personal Information relating to a third party.